Synthesis, radiolabeling, and pre-clinical evaluation of [44Sc]Sc-AAZTA conjugate PSMA inhibitor, a new tracer for high-efficiency imaging of prostate cancer | Zendy

Simona Ghiani | Zendy; Ivan Hawala | Zendy; Dezső Szikra | Zendy; György Trencsényi | Zendy; Zsolt Baranyai | Zendy; Gábor Nagy | Zendy; Adrienn Vágner | Zendy; Rachele Stefanìa | Zendy; Sushma Pandey | Zendy; Alessandro Maiocchi | Zendy

Open Access

Synthesis, radiolabeling, and pre-clinical evaluation of [44Sc]Sc-AAZTA conjugate PSMA inhibitor, a new tracer for high-efficiency imaging of prostate cancer

Author(s) -

Simona Ghiani,

Ivan Hawala,

Dezső Szikra,

György Trencsényi,

Zsolt Baranyai,

Gábor Nagy,

Adrienn Vágner,

Rachele Stefanìa,

Sushma Pandey,

Alessandro Maiocchi

Publication year - 2021

Publication title -

european journal of nuclear medicine and molecular imaging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.313

H-Index - 163

eISSN - 1619-7089

pISSN - 1619-7070

DOI - 10.1007/s00259-020-05130-0

Subject(s) - biodistribution , in vivo , scandium , chemistry , radiochemistry , dota , lncap , conjugate , prostate cancer , in vitro , chelation , cancer , biochemistry , medicine , organic chemistry , mathematical analysis , microbiology and biotechnology , mathematics , biology

The aim of this work was to demonstrate the suitability of AAZTA conjugated to PSMA inhibitor (B28110) labeled with scandium-44 as a new PET tracer for diagnostic imaging of prostate cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research